U-M to conduct clinical trial to test AstraZeneca COVID-19 vaccine

Author | Kelly Malcom

Michigan Medicine is partnering with the pharmaceutical company AstraZeneca for a Phase 3 clinical trial to test a vaccine against COVID-19. The AZD1222 COVID-19 VACCINE Study will research an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2).

The study will look at how well the investigational vaccine works and how safe it is. U-M will begin recruiting hundreds of participants for the trial immediately, until the trial is full. U-M is one of several U.S. sites supporting the AstraZeneca trial, with the aim of including 30,000 individuals over a period of two years.

“The importance of a safe and effective vaccine against COVID-19 cannot be overstated. The AstraZeneca Phase III trial will bring answers as to the effectiveness of this vaccine. At the end of the day, this kind of rigorous clinical trial with the commitment of Michigan Medicine and other study sites to safety will be a key step in realizing a vaccine that will save lives when one is developed,” says Marschall Runge, M.D., Ph.D., Dean, U-M Medical School, Executive Vice President, Medical Affairs and CEO, Michigan Medicine.

The AstraZeneca trial is one of several vaccine trials being funded through a public/private partnership under the U.S. Department of Health and Human Services called Operation Warp Speed. It is designed to accelerate the development of a life-saving vaccine to prevent COVID-19, while maintaining standards for safety and efficacy.

“We are proud to advance the University of Michigan's outstanding legacy of excellence in vaccine trials with this important clinical trial partnership. We hope one day soon to be able to announce a successful vaccine against COVID-19 and save lives,” says Mark Schlissel, M.D., Ph.D., president of the University of Michigan.

Phase I/II trials of the vaccine in more than 1000 people were completed earlier this year and demonstrated increased antibody responses against SARS-CoV-2 and no serious adverse effects.

For more information about the study, visit https://www.uofmhealth.org/covid19-vaccine or email [email protected].
Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Featured News & Stories stethoscope
Health Lab
More oversight of donated tissue products urgently needed, say experts and Michigan policymakers
A JAMA viewpoint outlines the tragic story of Shandra Eisenga, a patient who received spine surgery for back pain only to inexplicably contract tuberculosis.
 stained glass green blue purple orange pink
Health Lab
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis and—eventually—treatment
A study led by University of Michigan Health Rogel Cancer Center researchers identifies novel biomarkers in renal cell carcinomas.
 Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Breakthroughs in Personalized Medicine for Rare Kidney Disease
The NEPTUNE match study builds kidney atlas.
 uti written on empty roll of toliet paper on a toliet paper holder with hot pink background
Health Lab
How E. coli get the power to cause urinary tract infections
Research published in PNAS examines how the bacteria Escherichia coli, or E. coli—responsible for most UTIs—is able to use host nutrients to reproduce at an extraordinarily rapid pace during infection despite the near sterile environment of fresh urine.
Health Lab
Protecting heart health during pregnancy
Experts discuss pregnancy and heart health.
 woman holding face looking stressed on white couch in white shirt dark blue pants
Health Lab
Health costs top older adults’ list of concerns for people their age, poll finds
People over 50 of all backgrounds say they’re most concerned about various kinds of health costs affecting people their age, including insurance, prescriptions, medical care, dental care and home or longterm care.